Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-yCD/mutTKSR39rep-ADP Adenovirus + SBRT in Stage I/IIA NSCLC
NCT03029871Phase 1Withdrawn
- Start
- Jan 2017
- Primary completion
- Dec 2018
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ad5-ycd/muttksr39rep-adp in non-small cell lung cancer (NSCLC). Primary endpoint: Toxicity and maximum tolerated dose at 60 days. Planned start Jan 2017; status: withdrawn.
02
Drugs
ad5-ycd/muttksr39rep-adp
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03029871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029871.